SCHEMBL4826329

SCHEMBL4826329

CCOC(=O)c1c(C)nn(C)c1-c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A1 Q06495 8/20 0.55
ALDH1A1 P00352 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
NPSR1 Q6W5P4 2/20 0.48
GRM6 O15303 1/20 0.48
PRKCZ Q05513 1/20 0.48
KDM4E B2RXH2 2/20 0.47
HPGD P15428 2/20 0.47
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPT P10636 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
GABRA2 P47869 1/20 0.47
GABRB2 P47870 1/20 0.47
PKM P14618 1/20 0.47
MAPK1 P28482 1/20 0.47
FAAH O00519 1/20 0.46
LMNA P02545 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20551036 0.87 TSHR (0.56) SLC34A1ALDH1A1L3MBTL1NPSR1GRM6
SCHEMBL16060188 0.86 HTT (0.59) SLC34A1ALDH1A1L3MBTL1KDM4EMEN1
SCHEMBL21981603 0.86 LMNA (0.49) SLC34A1MEN1KMT2ANPC1RAB9A
SCHEMBL19209495 0.86 TSHR (0.57) SLC34A1ALDH1A1L3MBTL1NPSR1KDM4E
SCHEMBL21981602 0.81 CYP1A2 (0.50) SLC34A1KDM4EKMT2AMAPT
SCHEMBL3603486 0.81 GRM5 (0.56) SLC34A1ALDH1A1NPSR1NPC1RAB9A
SCHEMBL20075545 0.80 LMNA (0.53) SLC34A1ALDH1A1NPSR1KDM4EHPGD
SCHEMBL3595225 0.79 ALDH1A1 (0.49) SLC34A1ALDH1A1NPSR1KDM4EHPGD
SCHEMBL15750737 0.78 ALDH1A1 (0.56) SLC34A1ALDH1A1NPSR1KDM4EHPGD
SCHEMBL21974579 0.76 PDE4D (0.47) ALDH1A1L3MBTL1NPSR1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 SLC34A1 1621/4885ALDH1A1 2652/4885L3MBTL1 3524/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 SLC34A1 1621/4885ALDH1A1 2652/4885L3MBTL1 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.